酒石酸拉索昔芬 T7839

Product Introduction
Bioactivity


英文名: Lasofoxifene Tartrate

描述: Lasofoxifene Tartrate (CP-336156) 是一种非甾体类的雌激素受体选择性调节剂 (SERM)。

动物实验: Female DBA/1 mice were ovariectomised and subjected to CIA as a model of post-menopausal RA. Mice received treatment with Lasofoxifene (LAS), BZA, 17β-estradiol (E2) as reference or vehicle. Arthritis development was assessed and BMD was determined by peripheral quantitative CT of the femurs. Serologic markers of inflammation and cartilage destruction were analysed. Immune cells in lymph nodes were studied by flow cytometry[1].

体内活性: Lasofoxifene (LAS) and BZA reduced the clinical severity of arthritis as well as the grade of histologic synovitis and erosions on cartilage and bone.?Moreover, SERMs protected against generalised bone loss in CIA by increasing trabecular BMD.?Both SERMs decreased serum marker of cartilage destruction and LAS reduced serum IL-6 levels.?SERMs did not alter Th17 cells in lymph nodes as E2 did[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 6 mg/mL (10.65 mM)


关键字: osteoporosis | inhibit | Estrogen Receptor/ERR | arthritis | endocrine resistant | Lasofoxifene Tartrate | breast cancer | CP 336156 | Inhibitor | selective oestrogen receptor modulators | tartrate | oestrogen | CP336156 | Lasofoxifene

相关产品: Ethisterone | Liquiritigenin | Chrysin | Estrogen receptor modulator 8 | Isopsoralenoside | (Rac)-Acolbifene | WAY-200070 | Raloxifene hydrochloride | 4-hydroxyestrone-4-methyl ether | Prochloraz

相关库: Drug Repurposing Compound Library | Approved Drug Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Ovarian Cancer Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library | Endocrinology-Hormone Compound Library

酒石酸拉索昔芬 T7839信息由TargetMol中国为您提供，如您想了解更多关于酒石酸拉索昔芬 T7839报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途